Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers, Bacterial Infections

In brief

RPX2003 (biapenem) is being studied in combination with a beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.

Key facts

Study ID
NCT01702649
Run by
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
People needed
36
Starts
2012-08-01
Expected to finish
2012-11-01
Last updated by the study team
2012-12-03

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.